Selective Serotonin Reuptake Inhibitor-Related Extrapyramidal Symptoms in Autistic Children: A Case Series

Journal of Child and Adolescent Psychopharmacology

Volumn 14, Issue 1, 2004, Pages 143-147

  Sokolski, Kenneth N ^a,b   Chicz Demet, Aleksandra ^b   Demet, Edward M ^a,b  

^a VA LONG BEACH HEALTHCARE SYSTEM   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARBAMAZEPINE; FLUOXETINE; FLUVOXAMINE; PAROXETINE; RISPERIDONE; SEROTONIN UPTAKE INHIBITOR;

AGITATION; ANAMNESIS; ARTICLE; AUTISM; BRUXISM; CASE REPORT; CHILD; COMPULSION; DEPRESSION; DRUG EXPOSURE; DRUG INDUCED DISEASE; DYSTONIA; EXTRAPYRAMIDAL SYMPTOM; GRAND MAL SEIZURE; HUMAN; INTERVIEW; MALE; MENTAL INSTABILITY; MOOD DISORDER; OBSESSIVE COMPULSIVE DISORDER; OROFACIAL DYSKINESIA; PARENT; PHARMACEUTICAL CARE; PHYSICIAN; RATING SCALE; RETROSPECTIVE STUDY; SYMPTOM; TREATMENT WITHDRAWAL; VIDEOTAPE;

AUTISTIC DISORDER; BASAL GANGLIA DISEASES; CHILD; DYSKINESIA, DRUG-INDUCED; HUMANS; MALE; SEROTONIN UPTAKE INHIBITORS;

EID: 1942539088     PISSN: 10445463     EISSN: None     Source Type: Journal    
DOI: 10.1089/104454604773840599     Document Type: Article

References (24)

1. American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders, 4th ed. (DSM-IV). Washington (DC), American Psychiatric Association, 1994.
2. Andreassen OA, Meshul CK, Moore C, Jorgensen HA: Oral dyskinesias and morphological changes in rat striatum during long-term haloperidol administration. Psychopharmacology (Burl) 157:11-29, 2001.
3. Brown KW, White T, Wardlaw JM, Walker N, Foley D: Caudate nucleus morphology in tardive dyskinesia. Br J Psychiatry 169:631-636, 1996.
4. Caley CF: Extrapyramidal reactions from concurrent SSRI and atypical antipsychotic use. Can J Psychiatry 43:307-308, 1998.
5. Campbell M, Armenteros JL, Malone RP, Adams PB, Eisenberg ZW, Overall JE: Neuroleptic-related dyskinesias in autistic children: A prospective longitudinal study. J Am Acad Child Adolesc Psychiatry 36:835-843, 1997.
6. Chouinard G, Ross-Chouinard A, Annable L, Jones BD: The Extrapyramidal Symptom Rating Scale. Can J Neurol Sci 7:233, 1980.
7. Coyle JT: Psychotropic drug use in very young children. JAMA 283:1059-1060, 2000.
8. DeLong GR, Ritch CR, Burch S: Fluoxetine response in children with autistic spectrum disorders: Correlation with familial major affective disorder and intellectual achievement. Dev Med Child Neurol 44:652-659, 2002.
9. DeLong GR, Teague LA, McSwain KM: Effects of fluoxetine treatment in young children with idiopathic autism. Dev Med Child Neurol 40:551-562, 1998.
10. DeVane CL, Sallee FR: Serotonin selective reuptake inhibitors in child and adolescent psychopharmacology: A review of published experience. J Clin Psychiatry 57:55-66, 1996.
11. Fukuda T, Sugie H, Ito M, Sugie Y: Clinical evaluation of treatment with fluvoxamine, a selective serotonin reuptake inhibitor in children with autistic disorder [Japanese]. No To Hattatsu 33:314-318, 2001.
12. Gerber PE, Lynd LD: Selective serotonin reuptake inhibitor-induced movement disorders. Ann Pharmacother 32:692-698, 1998.
13. Hansen ES, Hasselbalch S, Law I, Bolwig TG: The caudate nucleus in obsessive-compulsive disorder. Reduced metabolism following treatment with paroxetine: A PET study. Int J Neuropsychopharmacol 5:1-10, 2002.
14. Hollander E, Kaplan A, Cartwright C, Reichman D: Venlafaxine in children, adolescents, and young adults with autism spectrum disorders: An open retrospective clinical report. J Child Neurol 15:132-135, 2000.
15. Jorgensen OS: Serotonin uptake inhibitors (SSRI) in the treatment of children and adolescents [Danish]. Ugeskr Laeger 160:7240, 1998.
16. Lane RM: SSRI-induced extrapyramidal side effects and akathisia: Implications for treatment. J Psychopharmacol 12:192-214, 1998.
17. Leo RJ: Movement disorders associated with the serotonin selective reuptake inhibitors. J Clin Psychiatry 57:449-454, 1996.
18. Magulac M, Landsverk J, Golshan S, Jeste DV: Abnormal involuntary movements in neuroleptic-naïve children and adolescents. Can J Psychiatry 44:368-373, 1999.
19. McCracken JT, McGough J, Shah B, Cronin P, Hong D, Aman MG, Arnold LE, Lindsay R, Nash P, Hollway J, McDougle CJ, Posey D, Swiezy N, Kohn A, Scahill L, Martin A, Koenig K, Volkmar F, Carroll D, Lancor A, Tierney E, Ghuman J, Gonzalez NM, Grados M, Vitiello B, Ritz L, Davies M, Robinson J, McMahon D; Research Units on Pediatric Psychopharmacology Autism Network: Risperidone in children with autism and serious behavioral problems. N Engl J Med 347:314-321, 2002.
20. Purcell AE, Jeon OH, Zimmerman AW, Blue ME, Pevsner J: Postmortem brain abnormalities of the glutamate neurotransmitter system in autism. Neurology 57:1618-1628, 2001.
21. Rosenberg DR, MacMaster FP, Keshavan MS, Fitzgerald KD, Stewart CM, Moore GJ: Decrease in caudate glutamatergic concentrations in pediatric obsessive-compulsive disorder patients taking paroxetine. J Am Acad Child Adolesc Psychiatry 39:1096-1103, 2000.
22. Sears LL, Vest C, Mohamed S, Bailey J, Ranson BJ, Piven J: An MRI study of the basal ganglia in autism. Prog Neuropsychopharmacol Biol Psychiatry 23:613-624, 1999.
23. Steingard RJ, Zimnitzky B, DeMaso DR, Bauman ML, Bucci JP: Sertraline treatment of transition-associated anxiety and agitation in children with autistic disorder. J Child Adolesc Psychopharmacol 7:9-15, 1997.
24. Zito JM, Safer DJ, dosReis S, Gardner JF, Boles M, Lynch F: Trends in the prescribing of psychotropic medications to preschoolers. JAMA 283:1025-1030, 2000.